+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Plasma Fractionation Market by Product Application End User: Global Opportunity Analysis and Industry Forecast, 2018-2028

  • PDF Icon

    Report

  • 205 Pages
  • November 2019
  • Region: Global
  • Allied Market Research
  • ID: 4989493
The global plasma fractionation market was valued at $16,823 million in 2018, and is expected to reach $30,536 million by 2026, registering a CAGR of 6.1% from 2019 to 2026. Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of the blood which is yellowish and holds blood cells. Plasma fractionation is carried out to separate high quality, proteinaceous products such as albumin, immunoglobulins, and others. These derived products are known as plasma derivatives obtained from fractionation. Moreover, these products are used in various medical fields such as in neurology, hematology, critical care, immunology, and others. For instance, in critical care, plasma is prescribed to prevent and stop bleeding. In addition, plasma products are widely used in clinical research laboratories and hospitals.



The factors that boost the growth of the plasma fractionation market include surge in geriatric population across the globe, which is predisposed to various rare diseases that require the use of plasma derivatives. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuel the growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward the growth of this market.
In addition, favorable governmental support to spread awareness related to the use of plasma derived products also fuels the growth of the plasma fractionation market. However, high cost of plasma derived products restricts the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.

The global plasma fractionation market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is divided into albumin, immunoglobulins, and coagulation factor VIII. Moreover, immunoglobulins are further divided into subcutaneous immunoglobulin (SCIG) and coagulation factor VIII. By application, the market is classified into neurology, hematology, immunology, critical care, and others. On the basis of end user, it is categorized into hospitals and clinical research laboratories. By country, it is analyzed across Russia, Kazakhstan, Indonesia, China (Including Taiwan), India, Saudi Arabia, Egypt, Vietnam, Argentina, Thailand, and Nigeria.

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current global plasma fractionation market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Product
  • Albumin
  • Immunoglobulins
  • Subcutaneous Immunoglobulin (SCIG)
  • Intravenous Immunoglobulin (IVIG)
  • Coagulation Factor

By Application
  • Neurology
  • Hematology
  • Immunology
  • Critical Care
  • Others

By End User
  • Hospitals
  • Clinical Research Laboratories

By Country
  • Russia
  • Kazakhstan
  • Indonesia
  • China (Including Taiwan)
  • India
  • Saudi Arabia
  • Egypt
  • Vietnam
  • Argentina
  • Thailand
  • Nigeria
  • Rest of the World

List of key players profiled in the report:
  • Grifols SA
  • Baxter International Inc
  • CSL LTD.
  • Bio Product Laboratory
  • Octapharma AG
  • Sanquin
  • Laboratoire Franais Du Fractionnement Et Des
  • Kedrion
  • Biotest
  • Takeda Pharmaceuticals

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • LFB S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List Of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings Of The Study
2.2. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter'S Five Forces Analysis
3.3.1. Bargaining Power Of Buyers
3.3.2. Bargaining Power Of Suppliers
3.3.3. Thereat Of New Entrants
3.3.4. Threat Of Substitutes
3.3.5. Intensity Of Competitive Rivalry
3.4. Top Player Positioning, 2018
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Geriatric Population Across The Globe Coupled With Rise In Prevalence Of Rare Diseases
3.5.1.2. Rise In Use Of Immunoglobulins In Areas Of Medicine
3.5.1.3. Increase In Number Of Plasma Collection Centers Across The Globe
3.5.2. Restraint
3.5.2.1. High Cost Of Plasma Derived Products
3.5.3. Opportunity
3.5.3.1. High Growth Potential In Emerging Economies
3.5.4. Impact Analysis
Chapter 4: Plasma Fractionation Market, By Product
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Albumin
4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Country
4.3. Immunoglobulins
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Type
4.3.2.1. Subcutaneous Immunoglobulin
4.3.2.1.1. Market Size And Forecast
4.3.2.2. Intravenous Immunoglobulin
4.3.2.2.1. Market Size And Forecast
4.3.3. Market Size And Forecast, By Country
4.4. Coagulation Factor Viii
4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Country
Chapter 5: Plasma Fractionation Market, By Application
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Neurology
5.2.1. Market Size And Forecast, By Region
5.3. Hematology
5.3.1. Market Size And Forecast, By Region
5.4. Immunology
5.4.1. Market Size And Forecast, By Region
5.5. Critical Care
5.5.1. Market Size And Forecast, By Region
5.6. Others
5.6.1. Market Size And Forecast, By Region
Chapter 6: Plasma Fractionation Market, By End User
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospitals
6.2.1. Market Size And Forecast, By Region
6.3. Clinical Research Laboratories
6.3.1. Market Size And Forecast, By Region
Chapter 7: Plasma Fractionation Market, By Country
7.1. Overview
7.1.1. Market Size And Forecast
7.2. Russia
7.2.1. Key Market Trends And Growth Opportunities
7.2.2. Market Size And Forecast, By Product
7.2.3. Market Size And Forecast, By Application
7.2.4. Market Size And Forecast, By End User
7.3. Kazakhstan
7.3.1. Key Market Trends And Growth Opportunities
7.3.2. Market Size And Forecast, By Product
7.3.3. Market Size And Forecast, By Application
7.3.4. Market Size And Forecast, By End User
7.4. Indonesia
7.4.1. Key Market Trends And Growth Opportunities
7.4.2. Market Size And Forecast, By Product
7.4.3. Market Size And Forecast, By Application
7.4.4. Market Size And Forecast, By End User
7.5. China (Including Taiwan)
7.5.1. Key Market Trends And Growth Opportunities
7.5.2. Market Size And Forecast, By Product
7.5.3. Market Size And Forecast, By Application
7.5.4. Market Size And Forecast, By End User
7.6. India
7.6.1. Key Market Trends And Growth Opportunities
7.6.2. Market Size And Forecast, By Product
7.6.3. Market Size And Forecast, By Application
7.6.4. Market Size And Forecast, By End User
7.7. Saudi Arabia
7.7.1. Key Market Trends And Growth Opportunities
7.7.2. Market Size And Forecast, By Product
7.7.3. Market Size And Forecast, By Application
7.7.4. Market Size And Forecast, By End User
7.8. Egypt
7.8.1. Key Market Trends And Growth Opportunities
7.8.2. Market Size And Forecast, By Product
7.8.3. Market Size And Forecast, By Application
7.8.4. Market Size And Forecast, By End User
7.9. Vietnam
7.9.1. Key Market Trends And Growth Opportunities
7.9.2. Market Size And Forecast, By Product
7.9.3. Market Size And Forecast, By Application
7.9.4. Market Size And Forecast, By End User
7.10. Argentina
7.10.1. Key Market Trends And Growth Opportunities
7.10.2. Market Size And Forecast, By Product
7.10.3. Market Size And Forecast, By Application
7.10.4. Market Size And Forecast, By End User
7.11. Thailand
7.11.1. Key Market Trends And Growth Opportunities
7.11.2. Market Size And Forecast, By Product
7.11.3. Market Size And Forecast, By Application
7.11.4. Market Size And Forecast, By End User
7.12. Nigeria
7.12.1. Key Market Trends And Growth Opportunities
7.12.2. Market Size And Forecast, By Product
7.12.3. Market Size And Forecast, By Application
7.12.4. Market Size And Forecast, By End User
7.13. Rest Of The World
7.13.1. Key Market Trends And Growth Opportunities
7.13.2. Market Size And Forecast, By Product
7.13.3. Market Size And Forecast, By Application
7.13.4. Market Size And Forecast, By End User
Chapter 8: Company Profiles
8.1. Baxter International Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Bio Products Laboratory
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Biotest Ag
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments
8.4. Csl Ltd.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Grifols Sa
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Kedrion Biopharma
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Lfb S. A
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Octapharma
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.9. Sanquin Blood Supply Foundation
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Takeda Pharmaceutical Company Limited
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
*Full List of Tables and Figures Available on Enquiry.

Executive Summary

According to the report titled, 'Plasma fractionation Market by Product, Application, and Provider: Global Opportunity Analysis and Industry Forecast, 2018-2028', the global plasma fractionation market size was valued at $16.82 billion in 2018, and is expected to reach $30.53 billion by 2028, registering a CAGR of 6.1% from 2018 to 2028.

Plasma fractionation is a separation technique, which is employed for obtaining plasma derivatives. There are different types of plasma derivatives available in the market such as albumin, immunoglobulins, and others. These products contain concentrated fractions of plasma protein, which is obtained by fractionation of plasma collected from a large number of donors. Furthermore, plasma derivatives are employed in different medical aspects such as hematology, neurology, critical care, and others. For instance, immunoglobulins are used in neurology to help patients suffering from multiple sclerosis, neuropathic pain, and others. Furthermore, these products are extensively used in research laboratories and hospitals owing to surge in awareness related to their use in various medical fields.

The factors that boost the growth of the plasma fractionation market include surge in geriatric population across the globe which is predisposed to various rare diseases which require the use of plasma derivatives. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuel the growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes to the growth of this market. In addition, favorable governmental support to spread awareness related to the use of plasma derived products also fuels the growth of the plasma fractionation market.

However, high cost of plasma derived products restricts the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period

The global plasma fractionation market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is divided into albumin, immunoglobulins, and coagulation factor VIII. Moreover, immunoglobulins are further divided into subcutaneous immunoglobulin (SCIG) and coagulation factor VIII. By application, it is divided into neurology, hematology, immunology, critical care, and others. On the basis of end user, it is bifurcated into hospitals and clinical research laboratories. By country, it is analyzed across Russia, Kazakhstan, Indonesia, China (Including Taiwan), India, Saudi Arabia, Egypt, Vietnam, Argentina, Thailand, and Nigeria.

In terms of value, by product, immunoglobulin is the largest segment in the plasma fractionation market and is also expected to exhibit the fastest growth rate during the forecast period. The growth of this segment is attributable to the diversified use of immunoglobulin in various disorders such as primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases. Furthermore, surge in research related to immunology across the globe is another factor that contributes toward the growth of the immunoglobulin market.

In terms of value, by application, neurology acquired the largest share of plasma fractionation market and is also the fastest growing segment during the forecast period. This is attributable to the surge in the neurological disorders that require plasma fractionation products for treatment. Furthermore, surge in the adoption of plasma fractionation products in the field of neurology is another major factor that contributes toward the growth of the market.

In terms of value, on the basis of end user, hospitals acquired the major share of the market and is also expected to register fastest growth rate during the forecast period owing to the rise in number of hospitals worldwide. Furthermore, plasma derivatives are employed in medical filed such as critical care, hematology, and others. The treatment for these medical conditions is performed in the specialized medical facilities by skilled professional present in hospitals. Therefore, factors aforementioned contribute to the growth of the market.

On the basis of country, China (including Taiwan) is expected to grow at the fastest growth rate during the forecast period. The growth is attributable to presence of large population which has a huge demand for plasma fractionation products. Furthermore, surge in various medical conditions that require the use of plasma fractionation products is another major factor that contributes to the growth of market.

Key Findings of the Plasma fractionation Market:
In terms of value, immunoglobulins segment occupied two-third share of the global plasma fractionation market in 2018.
By application, Neurology segment is anticipated to grow with the highest CAGR throughout the forecast period.
By application, others segment accounted for two-third share of the market in terms of value in 2018.
China (including Taiwan) is anticipated to grow at the highest rate during the Plasma Fractionation Market analysis period.

Companies Mentioned

  • Grifols SA
  • Baxter International Inc.
  • CSL LTD.
  • Bio Product Laboratory
  • Octapharma AG
  • Sanquin
  • Laboratoire Franais Du Fractionnement Et Des
  • Kedrion
  • Biotest
  • Takeda Pharmaceuticals.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...